查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1402559

吉格列汀市场：按药物类型、按配销通路、按最终用户、按患者人口统计、按地区

Gemigliptin Market, By Type of Drug, By Distribution Channel, By End User, By Patient Demographics, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年全球吉格列汀市场规模为17.9亿美元，预计2030年将达25.9亿美元，2023年至2030年复合年增长率为5.4%。

报告范围 报告详情
基准年 2022年 2023年市场规模 17.9亿美元
实际资料 2018-2021 预测期 2023-2030
预测期复合年增长率 5.40% 2030年市场规模预测 25.9亿美元
图 1. 吉格列汀全球市场占有率(%)，依地区划分，2023 年
吉格列汀市场-IMG1

Gemigliptin 是一种有效的选择性Dipeptidyl Peptidase-4 (DPP-4) 抑制剂，用于治疗第 2 型糖尿病。由于其独特的化学结构，它通过增强肠促胰岛素激素的作用来有效降低血糖值。这种口服药物透过促进葡萄糖依赖性胰岛素分泌和抑制升糖素释放而在血糖控制方面具有良好的效果。吉格列汀（DPP-4 抑制剂类新药）的安全性和有效性使其成为寻求改善血糖控制和降低低血糖风险的糖尿病患者的宝贵选择。该药物独特的化学结构和作用机制使其有别于其他抗糖尿病药物。吉格列汀通常每日一次口服治疗，为糖尿病患者提供便利。然而，正在进行的研究、策略行销以及配方和联合治疗的潜在创新旨在将吉格列汀定位为各种糖尿病管理环境中的有价值的选择。

市场动态：

糖尿病盛行率的上升、糖尿病意识和诊断的提高以及向口服抗糖尿病药物的转变预计将在预测期内推动全球吉格列汀市场的成长。此外，有利的法规环境预计也将推动预测期内全球吉格列汀市场的成长。新兴市场的扩张、联合治疗、专注于以患者为中心的方法、儿童使用、妊娠糖尿病等预计将为预测期内的全球吉格列汀市场提供成长机会。

然而，与现有药物的竞争、专利到期、学名药药竞争和安全性担忧预计​​将阻碍预测期内吉格列汀市场的成长。

本研究的主要特点

  • 本报告对吉格列汀市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR%）。
  • 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
  • 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数来介绍吉格列汀市场的主要企业。
  • 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
  • 吉格列汀市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 透过用于分析吉格列汀市场的各种策略矩阵，将促进相关人员的决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
  • 糖尿病盛行率上升
    • 抑制因素
  • 与现有药物的竞争
    • 机会
  • 新兴市场扩张
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 併购场景

第四章吉格列汀市场－冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章吉格列汀市场，依药物类型，2018-2030

  • 吉格列汀单一疗法
  • 吉格列汀联合治疗

第 6 章 吉格列汀市场，依配销通路，2018-2030

  • 医院药房
  • 零售药房
  • 网路药房

第 7 章 吉格列汀市场，依最终用户划分，2018-2030 年

  • 医院
  • 零售店及门诊设施
  • 其他（学术研究机构）

第 8 章 吉格列汀市场，依病患人口统计，2018-2030 年

  • 成人
  • 老年人

第9章吉格列汀市场，按地区，2018-2030

  • 北美洲
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 中东
  • GCC
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第10章竞争形势

  • Daewoong Pharmaceutical
  • Sanofi
  • LG Chem
  • Hanmi Pharmaceutical Co., Ltd.
  • Merck

第11章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6114

The global gemigliptin market size was valued at US$ 1.79 Bn in 2023 and is expected to reach US$ 2.59 Bn by 2030, grow at a compound annual growth rate (CAGR) of 5.4% from 2023 to 2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 1.79 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 5.40% 2030 Value Projection: US$ 2.59 Bn
Figure 1. Global Gemigliptin Market Share (%), by Region, 2023
Gemigliptin Market - IMG1

Gemigliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. With its unique chemical structure, gemigliptin effectively lowers blood glucose levels by enhancing the action of incretin hormones. This oral medication offers promising results in gycemic control by promoting glucose-dependent insulin secretion and suppressing glucagon release. As a newer entrant in the DPP-4 inhibitor class, Gemigliptin's safety profile and efficacy make it a valuable option for diabetes patients seeking improved glucose regulation and a reduced risk of hypoglycaemia. This medication is characterized by its unique chemical structure and mechanism of action, setting it apart from other antidiabetic drugs. Gemigliptin is typically prescribed as a once-daily oral treatment, providing convenience for patients managing their diabetes. However, ongoing research, strategic marketing, and potential innovations in formulation or combination therapies aim to position gemigliptin as a valuable option in the diverse landscape of diabetes management.

Market Dynamics:

The rising prevalence of diabetes, increasing awareness and diagnosis, and shift towards oral antidiabetic drugs are anticipated to drive growth of the global gemigliptin market over the forecast period. Moreover, a favorable regulatory environment is also expected to boost the growth of the global gemigliptin market over the forecast period. Expansion in emerging markets, combination therapies, a focus on patient-centric approaches, pediatric use, and gestational diabetes are expected to create growth opportunities for the global gemigliptin market during the forecast period.

However, competition from established drugs, patent expiry, generic competition, and safety concerns are expected to hamper growth of the gemigliptin market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the gemigliptin market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the gemigliptin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Daewoong Pharmaceutical, Sanofi, LG Chem, Hanmi Pharmaceutical Co., Ltd., and Merck
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The gemigliptin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the gemigliptin market

Detailed Segmentation:

  • Gemigliptin Market Segmentation, By Type of Drug:
    • Gemigliptin Monotherapy
    • Gemigliptin Combination Therapy
  • Gemigliptin Market Segmentation, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Gemigliptin Market Segmentation, By End User:
    • Hospitals
    • Clinics and Outpatient Facilities
    • Others (Academic and Research Institutes)
  • Gemigliptin Market Segmentation, By Patient Demographics:
    • Adult Population
    • Geriatric Population
  • Gemigliptin Market Segmentation, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profile:
    • Daewoong Pharmaceutical
    • Sanofi
    • LG Chem
    • Hanmi Pharmaceutical Co., Ltd.
    • Merck

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Gemigliptin , By Type of Drug
    • Market Gemigliptin , By Distribution Channel
    • Market Gemigliptin , By End User
    • Market Gemigliptin , By Patient Demographics
    • Market Gemigliptin , By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Rising prevalence of diabetes
    • Restraints
  • Competition from established drugs
    • Opportunities
  • Expansion in emerging markets
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Gemigliptin Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Gemigliptin Market , By Type of Drug, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Gemigliptin Monotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Gemigliptin Combination Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Gemigliptin Market , By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Gemigliptin Market , By End User, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Retail Clinics and Outpatient Facilities
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others (Academic and Research Institutes)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Gemigliptin Market , By Patient Demographics, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Adult Population
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Geriatric Population
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Gemigliptin Market , By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Country, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Country 2019-2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Daewoong Pharmaceutical
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • LG Chem
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Hanmi Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

11. Section

  • Research Methodology
  • About us